Hepatitis E (HEV) is most common in developing countries with inadequate water supply and environmental sanitation. The virus is enterically transmitted via the faecal-oral route and has been responsible for many large outbreaks. Every year it is estimated to infect about 20 million people, cause 3.3 million incident cases and claim 70,000 lives. Although HEV usually causes a self-limited acute illness in humans the virus disproportionately affects pregnant women with a probability of death estimated at ~20%.
In December 2011 the first HEV vaccine "Hecolin" was approved by China's State Food and Drug Administration (SFDA). The product is marketed by the subsidary company Innovax formed by Yangshengtang Group and Xiamen University in Fujian province. Hecolin is pending the WHO prequalification program so could be used outside of China in the future.
This MarketVIEW product contains an executive presentation with an MS Excel-based model which forecasts the potential commercial value of Hepatitis E Virus (HEV) vaccines across the private sector of highly endemic and endemic markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with timeframe, pricing and penetration estimates for all adult risk groups (>16 yrs) including immunocompromised, women of child bearing-age and military personnel. treatments.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL